tiprankstipranks
Trending News
More News >
C4 Therapeutics (CCCC)
NASDAQ:CCCC
US Market
Advertisement

C4 Therapeutics (CCCC) AI Stock Analysis

Compare
509 Followers

Top Page

CCCC

C4 Therapeutics

(NASDAQ:CCCC)

Rating:53Neutral
Price Target:
$2.50
▲(14.68%Upside)
C4 Therapeutics' overall stock score is primarily impacted by its financial performance challenges, with ongoing losses and cash flow issues needing urgent attention. Technical analysis provides some positive momentum, but the high volatility and valuation concerns due to negative earnings limit the appeal. Investors should consider the significant risks associated with the current financial state.
Positive Factors
Partnership Opportunities
Management intends to partner cemsi to maximize value, which could result in a rally of shares upon an announcement.
Product Potential
CFT1946 has the potential to replace BRAF inhibitors and be CCCC's first wholly-owned commercial product.
Valuation
The company's valuation at an EV of ~$50MM suggests a significant opportunity for growth, as the market currently assigns no value to certain promising programs.
Negative Factors
Market Competition
Competitors in the market could challenge the potential growth of CFT1946 and its ability to replace existing BRAF inhibitors.
Regulatory Uncertainty
The process of determining the dosing regimen for cemsi highlights challenges related to regulatory approval and competitive profiling.

C4 Therapeutics (CCCC) vs. SPDR S&P 500 ETF (SPY)

C4 Therapeutics Business Overview & Revenue Model

Company DescriptionC4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
How the Company Makes MoneyC4 Therapeutics generates revenue primarily through strategic collaborations and partnerships with other biotechnology and pharmaceutical companies. These agreements typically involve upfront payments, milestone payments, and potential royalties based on the successful development and commercialization of TPD therapies. The company's partnerships often focus on leveraging its TORPEDO platform to advance novel drug candidates through various stages of clinical development. While C4 Therapeutics is actively engaged in research and development activities, its revenue model is heavily reliant on these collaborations to fund its operations and growth initiatives.

C4 Therapeutics Financial Statement Overview

Summary
C4 Therapeutics faces significant financial challenges, with persistent losses impacting profitability and cash flows. While the balance sheet remains relatively stable, the company needs to address its operational inefficiencies to improve financial health. Strategic adjustments may be necessary to enhance revenue generation and cost management to achieve sustainable growth.
Income Statement
42
Neutral
The income statement reveals a company struggling with profitability. The TTM (Trailing-Twelve-Months) shows negative EBIT and net income, indicating operational challenges. Although there's a modest revenue growth of 11.8% from the previous year, margins remain negative, suggesting ongoing difficulties in cost management or revenue generation.
Balance Sheet
55
Neutral
The balance sheet shows a reasonable equity ratio of 61.07%, indicating a solid capital structure with more assets funded by equity. However, the debt-to-equity ratio of 0.33 reflects manageable leverage but could pose risks if financial performance does not improve. Return on equity remains negative due to ongoing losses.
Cash Flow
48
Neutral
Cash flow analysis indicates issues with cash generation, as both operating and free cash flows are negative in the TTM (Trailing-Twelve-Months). The operating cash flow to net income ratio is negative, pointing to inefficiencies in converting sales into cash, while free cash flow is deteriorating, signaling cash management challenges.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue35.58M20.76M31.10M45.78M33.20M
Gross Profit35.58M-96.95M23.52M42.88M-44.27M
EBITDA-103.37M-122.10M-124.28M-78.84M-62.89M
Net Income-105.32M-132.49M-126.50M-86.04M-66.33M
Balance Sheet
Total Assets349.60M376.45M430.84M506.76M400.14M
Cash, Cash Equivalents and Short-Term Investments244.90M253.68M337.12M309.28M371.69M
Total Debt65.76M70.98M87.15M42.88M22.92M
Total Liabilities133.62M130.34M141.61M117.16M119.35M
Stockholders Equity215.99M246.11M289.23M389.61M280.79M
Cash Flow
Free Cash Flow-65.34M-108.55M-111.44M-88.24M-67.90M
Operating Cash Flow-65.16M-106.84M-105.94M-86.97M-67.25M
Investing Cash Flow-51.27M158.35M58.42M-189.34M-190.50M
Financing Cash Flow45.34M45.49M1.15M171.40M348.93M

C4 Therapeutics Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price2.18
Price Trends
50DMA
1.68
Positive
100DMA
1.68
Positive
200DMA
3.00
Negative
Market Momentum
MACD
0.19
Negative
RSI
57.47
Neutral
STOCH
41.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCCC, the sentiment is Neutral. The current price of 2.18 is above the 20-day moving average (MA) of 2.00, above the 50-day MA of 1.68, and below the 200-day MA of 3.00, indicating a neutral trend. The MACD of 0.19 indicates Negative momentum. The RSI at 57.47 is Neutral, neither overbought nor oversold. The STOCH value of 41.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CCCC.

C4 Therapeutics Risk Analysis

C4 Therapeutics disclosed 73 risk factors in its most recent earnings report. C4 Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

C4 Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
53
Neutral
$160.48M-45.55%98.56%37.97%
52
Neutral
$7.59B0.18-63.14%2.16%16.34%0.64%
46
Neutral
$103.61M-59.45%48.92%
43
Neutral
$100.24M-62.34%86.65%
41
Neutral
$97.98M-62.04%-61.95%
36
Underperform
$187.14M-49.72%
33
Underperform
$274.91M-125.43%2.98%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CCCC
C4 Therapeutics
2.18
-4.12
-65.40%
ZNTL
Zentalis Pharmaceuticals
1.44
-2.68
-65.05%
VOR
Vor Biopharma
2.42
1.50
163.04%
CLYM
Climb Bio
1.60
-6.54
-80.34%
ZURA
Zura Bio
1.62
-2.11
-56.57%
KYTX
Kyverna Therapeutics, Inc.
4.33
-4.42
-50.51%

C4 Therapeutics Corporate Events

Executive/Board ChangesShareholder MeetingsBusiness Operations and Strategy
C4 Therapeutics Holds Annual Stockholders Meeting
Neutral
Jun 18, 2025

On June 18, 2025, C4 Therapeutics held its Annual Meeting of Stockholders, where key decisions were made regarding the company’s governance and operational strategies. Stockholders elected three Class II directors, approved executive compensation, ratified KPMG LLP as the independent auditor, and agreed to amend the company’s certificate of incorporation to double the authorized shares of common stock, reflecting strategic growth ambitions.

The most recent analyst rating on (CCCC) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.

Product-Related AnnouncementsFinancial Disclosures
C4 Therapeutics Updates on Cemsidomide Clinical Trial
Neutral
May 7, 2025

On May 7, 2025, C4 Therapeutics announced updates from its Phase 1 clinical trial of cemsidomide, a small-molecule degrader for multiple myeloma (MM) and non-Hodgkin’s lymphomas (NHL). The trial’s dose escalation phase in MM is complete, with the 100 µg QD dose level showing a 50% overall response rate, including a complete response in one patient. The trial continues for NHL, with the maximum tolerated dose not yet reached. C4T plans to prioritize cemsidomide’s development and expects regulatory feedback by mid-2025 to support further clinical development in 2026. Financially, C4T reported a net loss of $26.3 million for Q1 2025, with cash reserves expected to fund operations into 2027.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 12, 2025